This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Areas
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
BEY - Banner Image

Beyonttra is indicated for the treatment of

wild-type or variant transthyretin amyloidosis

in adult patients with cardiomyopathy (ATTR-CM)

Navigation ATTR-CM Diagnosis resources
Navigating ATTR-CM Diagnosis
Beyonttra®▼ (acoramidis) | Explore resources on Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
PP-PF-CAR-GB-0060, October 2025
CV Summit 2025 - ATTR-CM Highlight Content Card
Cardiovascular Summit 2025 - ATTR-CM Highlights
Explore the Key Highlights on Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | Beyonttra®▼ (acoramidis)
PP-BEY-GB-0085, November 2025
HF-IMPACT Hub
HF-IMPACT Hub
Explore Resources and Events Focussed on Improving Management and Prognosis Through Advance Cardiac Training
PP-BEY-GB-0074, October 2025

PP-BEY-GB-0213 | March 2026

    • 1
      UK Summary of Product Characteristics for BEYONTTRA (acoramidis)